Aurinia Pharmaceuticals (AUPH) Return on Capital Employed (2021 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Return on Capital Employed came in at 19.12% in Q1 2026, up 1249.0% YoY from 1.42% in Q1 2025, and down 0.55% on a QoQ basis from 19.22% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Return on Capital Employed (2021 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 6 years of Return on Capital Employed data on file, last reported at 19.12% in Q1 2026.
- Quarterly Return on Capital Employed rose 1249.0% year-over-year to 19.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19.12% (up 1249.0% YoY) and the FY2025 annual result came in at 18.82%, up 1986.0% from the prior year.
- Return on Capital Employed eased to 19.12% in Q1 2026, from 19.22% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.22% in Q4 2025 to a low of 34.21% in Q1 2022.
- A 5-year average of 9.83% and a median of 16.34% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 373 bps — and 2025, when it soared 2592 bps.
- Tracing AUPH's Return on Capital Employed over 5 years: stood at 25.72% in 2022, then increased by 25 bps to 19.33% in 2023, then jumped by 95 bps to 1.04% in 2024, then soared by 1955 bps to 19.22% in 2025, then fell by 1 bps to 19.12% in 2026.
- The last three Return on Capital Employed figures came in at 19.12% (Q1 2026), 19.22% (Q4 2025), and 15.95% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 22.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.90% |
| Mar 31, 2026 | 19.12% |
| Dec 31, 2025 | 19.22% |
| Sep 30, 2025 | 15.95% |
| Jun 30, 2025 | 12.22% |
| Mar 31, 2025 | 6.62% |
| Dec 31, 2024 | -1.04% |
| Sep 30, 2024 | -7.14% |
| Jun 30, 2024 | -13.70% |
| Mar 31, 2024 | -16.34% |
| Dec 31, 2023 | -19.33% |
| Sep 30, 2023 | -18.85% |
| Jun 30, 2023 | -19.00% |
| Mar 31, 2023 | -24.61% |
| Dec 31, 2022 | -25.72% |
| Sep 30, 2022 | -26.18% |
| Jun 30, 2022 | -34.12% |
| Mar 31, 2022 | -34.21% |
| Dec 31, 2021 | -43.97% |
| Sep 30, 2021 | -46.50% |